Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: Immune modulation in solid tumors: a phase 1b study of RO6870810 (BET inhibitor) and atezolizumab (PD-L1 inhibitor)

Fig. 2

Changes in Target Lesion Size and Best Overall Response. Each bar represents the response of an individual patient, measured according to RECIST overall response criteria. The y-axis corresponds to the maximum percentage change from baseline in sum of longest diameters (SLD) in target lesions. Colors indicate the best overall response. Out of 36 patients, 31 were evaluable for clinical response. Two patients who exhibited a decrease in target lesion size were still classified as having progressive disease due to progression in non-target lesions or the appearance of new lesions

Back to article page